Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint blockade (ICB) therapy shows promise but requires new strategies to improve efficacy.
• The interferon-gamma (IFNγ) pathway is known to influence ICB response, but IFNγ-independent pathways, like tumor necrosis factor (TNF), are less understood.
• Limited TNF antitumor activity in tumors correlates with poor response to ICB.

Purpose of the Study:

• To identify novel targets for enhancing ICB therapy by investigating IFNγ-independent signaling pathways.
• To explore the role of the TNF pathway in tumor response to ICB and identify genetic modifiers of TNF sensitivity.

Main Methods:

• Genome-wide CRISPR/Cas9 screening was employed in IFNγ receptor-deficient tumor cells to identify genetic modifiers of sensitivity to CD8 T cell-mediated killing.
• Analysis of clinical data to correlate TNF pathway activity with tumor status and ICB response.
• Functional studies to investigate the mechanism by which TRAF2 ablation impacts TNF signaling and tumor cell apoptosis.

Main Results:

• A genome-wide screen identified several components of the TNF pathway as critical for ICB response.
• TRAF2 was identified as a key regulator, with its ablation redirecting TNF signaling towards RIPK1-dependent apoptosis.
• Loss of TRAF2 enhanced the efficacy of cIAP inhibition and ICB, demonstrating a synergistic effect.

Conclusions:

• Reducing the TNF cytotoxicity threshold by targeting TRAF2 can sensitize tumors to immunotherapy.
• The TNF pathway, particularly TRAF2, represents a promising target for combination therapies to improve ICB outcomes.
• This study highlights the potential of targeting IFNγ-independent pathways to overcome resistance to cancer immunotherapy.